摘要
目的探讨二甲双胍对伴胰岛素抵抗的多囊卵巢综合征(PCOS)患者血清白脂素(Asprosin)水平的影响。方法选取中国石油大学医院2019年1月~2019年10月门诊及住院的初诊PCOS患者55例,给予二甲双胍治疗3个月,检测受试者治疗前后血清Asprosin浓度、相关血生化代谢指标及性激素水平变化,测量并计算腰臀比(WHR)、体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)和游离雄激素指数(free androgen index,FAI)。分析二甲双胍对PCOS患者血清Asprosin水平的影响及其与其他代谢指标变化的相关性。结果治疗后PCOS组患者血清Asprosin浓度较治疗前降低(P<0.05),BMI、空腹血糖(FBG)、甘油三酯(TG)、空腹胰岛素(FINS)、HOMA-IR、雄激素(T)、黄体生成素(LH)、FAI均较治疗前降低(P<0.05),性激素结合球蛋白(SHBG)治疗后显著高于治疗前(P<0.05)。相关回归分析显示,BMI、TG、HOMA-IR、FAI的降低分别与血清Asprosin水平的降低均呈正相关(r=0.287、0.865、0.425、0.291,P<0.05或0.01)。多元逐步回归分析显示,HOMA-IR及TG的下降为血清Asprosin的下降的独立相关因素(β=0.208、0.810,P<0.05)。结论二甲双胍可降低PCOS患者血清Asprosin浓度水平,可能与其改善胰岛素抵抗及降脂作用有关。
Objective To study the effects of metformin treatment on serum asprosin levels in patients with polycystic ovary syndrome(PCOS).Methods 55 patients with PCOS in outpatient department and inpatient ward were selected from January 2019-October 2019.All the patients were given metformin 0.5g/d for 3 months.Serum asprosin level,metabolism-related blood biochemical indices and sexual hormone level were measured,and waist-hip ratio(WHR),BMI,insulin resistance of homeostasis model assessment(HOMA-IR)and free androgen index(FAI)were calculated.The correlation between the change of asprosin level and other metabolic indices after metformin treatment was analyzed by linear correlation and multiple linear regression.Results The asprosin level[(3.64±0.67)ng/mL vs(6.37±0.31)ng/mL,P<0.05)],BMI,fasting blood glucose(FBG),triglyceride(TG),fasting insulin(FINS),HOMA-IR,testosterone(T),Luteinizing Hormone(LH),FAI were lower significantly and SHBG level were higher than that after metformin treatment.The decrease of the serum asprosin level of the PCOS patients was positively correlated with the decrease of BMI,TG,HOMA-IR and FAI.Stepwise multiple regression analysis showed that the decrease of HOMA-IR and TG were independent risk factors for the decrease of serum asprosin level in the PCOS patients(β=0.208,0.810,P<0.05).Conclusion Metformin treatment can reduce the level of serum asprosin in PCOS patients,which may be related to improving insulin resistance and antilipemic effect.
作者
郭娅棣
高燕燕
刘建国
邓玉杰
GUO Yadi;GAO Yanyan;LIU Jianguo;DENG Yujie(Department of Endocrinology, China University of Petroleum (Huadong) Hospital, Qingdao 266580, Shandong, China;Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao 266580, Shandong, China;College of Chemical Engineering, China University of Petroleum (Huadong), Qingdao 266580, Shandong, China)
出处
《西部医学》
2021年第1期62-65,共4页
Medical Journal of West China
基金
国家自然科学基金面上项目(21473256)
国家自然科学基金青年基金(81600684)
山东省自然科学基金(ZR2016HQ16)。
